Divestment

Prosensa

Prosensa developed RNA-based therapies for Duchenne muscular dystrophy.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Netherlands
Fund: LSP 3, LSP 4
Entry: 2007
Exit: 2015

Responsible Partner

Martijn Kleijwegt

Martijn Kleijwegt

Partner

News

October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Prosensa | EQT Portfolio